This morning, during a live webcast, we’ll discuss topline results from our HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis with cardiomyopathy. Access the webcast: https://bit.ly/374c75E #RNAiTherapeutics #siRNA
Bravo team. Outstanding as always
Chief Executive Officer at USA and International Research Inc.
2wLooking forward to the insights from the HELIOS-B Phase 3 study webcast on vutrisiran! Exciting developments in RNAi therapeutics for ATTR amyloidosis.